iMDx reports Q1 net loss $4.3M; signs first GALACTIC trial site, advances FDA submission

Insight Molecular Diagnostics Inc.

2026-Q1 EPS reported -$0.12 vs consensus -$0.27 ▲ beat (+55.0%)

Q1 revenue ~$32K, gross profit $15K; net loss $4.3M ($0.12/share); non-GAAP net loss $9.6M ($0.28/share).
Signed first clinical trial agreement for GALACTIC registry with a top-10 U.S. kidney transplant center.
Non-GAAP operating expenses $4.4M including $5.9M non-cash gain; R&D down 15% sequentially.
Expect FDA marketing authorization for GraftAssureDx later 2026; productive FDA dialogue ongoing.
Small RUO orders from Switzerland and pending from Southeast Asia; first U.S. orders anticipated later this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.